Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. - sprookjes - yvandenbroek - TriplyDB

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

http://www.wikidata.org/entity/Q37411178

about

Targeted immunotherapy for pediatric solid tumors Chemoresistance, cancer stem cells, and miRNA influences: the case for neuroblastoma ALK and ROS1 as a joint target for the treatment of lung cancer: a review Emerging importance of ALK in neuroblastoma Targeting EML4-ALK driven non-small cell lung cancer (NSCLC)Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.Second- and third-generation ALK inhibitors for non-small cell lung cancer Molecular pathogenesis of peripheral neuroblastic tumors Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum Identification of novel tumor-associated cell surface sialoglycoproteins in human glioblastoma tumors using quantitative proteomics PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.ALK-activating homologous mutations in LTK induce cellular transformation.Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome.Therapeutic targets for neuroblastomas.Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK.The potential for crizotinib in non-small cell lung cancer: a perspective review Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma Immunotherapy targets in pediatric cancer.ALK Inhibitors, a Pharmaceutical Perspective.ALK+ anaplastic large cell lymphoma exhibits phosphatidylinositol-3 kinase/Akt activity with retained but inactivated PTEN--a report from the Children's Oncology Group.SEC31A-ALK Fusion Gene in Lung Adenocarcinoma.Anaplastic lymphoma kinase protein expression predicts micrometastases and prognosis for patients with hepatocellular carcinoma Lack of TNFalpha expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+ TCL) cells from apoptosis Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.ALK: a tyrosine kinase target for cancer therapy.Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer.Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.Inhibitors of anaplastic lymphoma kinase: a patent review.New drug therapies in peripheral T-cell lymphoma.Treating ALK-positive lung cancer--early successes and future challenges.ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.Anaplastic lymphoma kinase as a therapeutic target.New insights into the genetics of neuroblastoma.Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.Journey of the ALK-inhibitor CH5424802 to phase II clinical trial.Anaplastic large cell lymphoma in children and adolescents.Targeted therapies for sarcomas: new roles for the pathologist.

P2860

Q26747703-D6C71B77-05FA-450B-82E9-103E61425678 Q26800007-A0763B27-7BF5-4617-BE04-520D281FC918 Q26851392-225939C0-95DD-471A-89CD-D35738A4695A Q26858819-F5826251-A36C-44C7-9BAA-DFC9E62AFD1D Q27002155-4A091F24-21FD-4F61-A3A6-16716118EB5F Q27851589-75C150D6-2BB9-4440-A3FF-111AEB4058F6 Q27851681-A2EB084C-6F0D-4133-B3C3-8BEDFDB33F41 Q28072496-69F1DDBA-DF2B-42D5-9709-C5E15ADD30D3 Q28271405-ECB98403-4C2A-485D-A93E-7947F63873CB Q28298351-75E3C197-E959-40D3-ACF3-1D2B635F1D57 Q28544645-F8935816-3C36-444E-B7CF-F368D291C59E Q33721880-7D36F56D-B23F-422E-94F2-F85A91E9BDEB Q34162940-334D4A20-50E3-4F05-821C-0CB0627C860E Q34480771-CA4D065D-B5CF-4528-9A39-DA872795B24C Q34560877-70FCC9AB-45E6-42D9-8619-7260A0361C62 Q34662576-B716C2DC-E6E0-46D8-AD8C-AF1955E5CF8D Q35086721-86F78847-4846-40F3-9437-9EC25D9F01C7 Q35534514-705E62E2-12C5-426F-BEB0-1D93635815A6 Q35623435-DFDF46B4-5C81-42E2-9789-862C9D6BF4BB Q35971029-E9DB958C-A366-42F0-9226-515BF97F4509 Q35972157-CD761403-86C1-42A6-9118-57F99EAF8267 Q36094893-9AE5808B-D585-46BD-B3D8-05F5BCB9C1E6 Q36482476-F3A82DEB-61C4-4A41-BFCD-8AFF741ECB62 Q36502649-816833AF-080E-4A7C-B4ED-F78C360E2DD1 Q37354193-99EC1C4B-DA3B-4989-AFB1-267509309D45 Q37412853-4FBFE3E4-F76A-4AE8-BF6D-4D67B26D35B2 Q37518624-5FB3302D-A48E-44D8-B3FF-B5D0AC2E0DA5 Q37562866-29F9A302-1B28-4446-A489-42446166ACAC Q37604076-02631A79-BD70-4A4C-93D1-42CE1277B02B Q37801664-B58BE874-5CB7-43BA-8DBD-6D244BC22DF6 Q37854715-D0286933-42D2-4B6A-8CD7-40965D982DDD Q37999657-969DF928-C05C-4339-A37E-10E95E1A05CF Q38010052-56CEFE3F-EA3B-49C1-BDDC-B84BD86BE1F4 Q38042570-139019CD-5882-4E8F-AC36-E41A4D2C9EFF Q38045455-4E01E134-868B-4EA3-8E05-74AA0FD8CC3C Q38074875-75CABF49-AA0E-4C5A-BDEE-3297E9679AD6 Q38079518-61356B53-AB48-4664-A6EA-493B0937FFF7 Q38108766-2454FDC8-2B2C-40B6-BB98-DA033C61C192 Q38113829-88B9741E-DA17-4C44-912A-92A01988540A Q38151788-D032D5FE-9EC3-41E0-AD60-7E4D04D1BF21

P2860

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

http://www.wikidata.org/entity/Q37411178

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Anaplastic lymphoma kinase: ro ...... bitor development for therapy.

@en

Anaplastic lymphoma kinase: ro ...... bitor development for therapy.

@nl

type

label

Anaplastic lymphoma kinase: ro ...... bitor development for therapy.

@en

Anaplastic lymphoma kinase: ro ...... bitor development for therapy.

@nl

prefLabel

Anaplastic lymphoma kinase: ro ...... bitor development for therapy.

@en

Anaplastic lymphoma kinase: ro ...... bitor development for therapy.

@nl

P1433

Q37411178-21645442-6DFE-44F1-A122-63436D3E1ACC

P1476

Q37411178-CA33A94C-EBB8-4E0B-9746-B782DE69C536

P2093

Q37411178-1DCB4DC4-5AA2-43AF-8EE0-CA1533DDFFDD

Q37411178-7ED06049-232E-4060-91EA-2A03BD94B834

Q37411178-8C453C5A-7B6A-4FDA-A890-717971D3AD4B

Q37411178-93FC757D-65EB-4B55-9F1E-C660214E7000

Q37411178-ACEDD3FE-163E-4B5C-A734-CFCF7B95398D

Q37411178-C77E82EA-D469-4142-B15B-664815BA649A

Q37411178-DC3BE0F6-DED0-4F00-ABE3-B9B4CC42B84D

Q37411178-EDECBB66-4C55-4B62-966A-E47C67C422C7

Q37411178-FC0C74A0-524D-4699-A2EC-BE19522AAF37

P2860

Q37411178-008E2C2B-D031-4F11-94BF-562847742D17

Q37411178-01804F65-2CB5-4175-B6F2-EA2909C89E26

Q37411178-025121B9-B579-4F74-9B9A-E607D1FE2C8C

Q37411178-028569A8-A117-4940-8989-8D7CBDD9DBF3

Q37411178-03CFFAC2-1564-4F25-9548-4B6D2253F1F0

Q37411178-0505E2B9-67CF-4F0D-965D-64315024AE63

Q37411178-0808F6BF-7BCB-41C0-895C-F337E52F4C90

Q37411178-090CFE63-C5F9-44C8-81CC-A57188DBFDDF

Q37411178-09628C74-EEF9-43BD-81E9-769B01760F22

Q37411178-0C68349D-C9F2-4947-ACD5-B60E7B7FC5BD

P304

Q37411178-B107AF11-965A-47E6-8F06-11147AEF47BA

P31

Q37411178-97764D61-ED37-46FE-A9C5-56B0E175C661

P356

Q37411178-F70C98B7-3BFC-419C-B8E0-DB1F6F8DE1DE

P433

Q37411178-C4580C81-7498-4A3E-A3A5-7041216CBAA1

P478

Q37411178-2EAFEC53-2E8D-4537-A301-C9E82D42A92B

P577

Q37411178-6597D538-1E60-4D0C-958A-189F5567645F

P5875

Q37411178-FD33C2DF-3A12-4DF2-9ABA-30DF4F2E904B

P698

Q37411178-FC4495EB-1D80-422E-9927-E1FC5F203570

P921

Q37411178-AF9C069B-F453-4D5D-9211-416684248974

P932

Q37411178-B93D8D30-2362-40BF-A634-3E9E6B45563E

P356

14737140.9.3.331

P1433

Expert Review of Anticancer Therapy

P1476

Anaplastic lymphoma kinase: ro ...... bitor development for therapy.

@en

P2093

A Thomas Look

http://www.w3.org/2001/XMLSchema#string

Jake Slavish

http://www.w3.org/2001/XMLSchema#string

Liquan Xue

http://www.w3.org/2001/XMLSchema#string

Qin Jiang

http://www.w3.org/2001/XMLSchema#string

Rani E George

http://www.w3.org/2001/XMLSchema#string

Stephan W Morris

http://www.w3.org/2001/XMLSchema#string

Thomas R Webb

http://www.w3.org/2001/XMLSchema#string

Walter B Rentrop

http://www.w3.org/2001/XMLSchema#string

Xiaoli Cui

http://www.w3.org/2001/XMLSchema#string

P2860

Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta

Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation

Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity

Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity

Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)

Identification of ALK as a major familial neuroblastoma predisposition gene

Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas

TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors

P304

331-356

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.9.3.331

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24190708

http://www.w3.org/2001/XMLSchema#string

P698

19275511

http://www.w3.org/2001/XMLSchema#string

P921

P932

2780428

http://www.w3.org/2001/XMLSchema#string